High-throughput chemiluminometric determination of prostate-specific membrane antigen mRNA in peripheral blood by RT-PCR using a synthetic RNA internal standard

被引:4
作者
Emmanouilidou, E
Ioannou, PC [1 ]
Christopoulos, TK
机构
[1] Univ Athens, Dept Chem, Athens 15771, Greece
[2] Univ Patras, Dept Chem, Patras 26500, Greece
[3] Inst Chem Engn & High Temp Chem Proc, Patras 26500, Greece
关键词
quantitative RT-PCR; PSMA mRNA; peripheral blood; chemiluminescence; hybridization;
D O I
10.1007/s00216-004-2719-6
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
A quantitative reverse transcriptase polymerase chain reaction (RT-PCR) method, employing internal standard (IS) RNA and a simplified chemiluminometric hybridization assay, is described for the determination of prostate-specific membrane antigen (PSMA) mRNA. The recombinant RNA IS has the same binding sites and size as the amplified PSMA mRNA. Biotinylated PCR products (263 bp) from PSMA mRNA and RNA IS are captured in microtiter wells coated with streptavidin, and hybridized with alkaline phosphatase-conjugated probes. The bound alkaline phosphatase (AP) is measured by using a chemiluminogenic substrate. The ratio of the luminescence values obtained for PSMA mRNA and the RNA IS is a linear function of the initial amount of PSMA mRNA present in the sample before RT-PCR. The linear range extends from 500 to 5,000,000 PSMA mRNA copies and the overall reproducibility of the assay, including RT-PCR and hybridization, ranges from 7.4 to 16.6%. Samples containing total RNA from PSMA-expressing LNCaP cells give luminescence ratios linearly related to the number of cells in the range 0.5-5,000 cells.
引用
收藏
页码:90 / 97
页数:8
相关论文
共 26 条
  • [1] Can the reverse transcriptase-polymerase chain reaction for prostate specific antigen and prostate specific membrane antigen improve staging and predict biochemical recurrence?
    Adsan, Ö
    Cecchini, MG
    Bisoffi, M
    Wetterwald, A
    Klima, I
    Danuser, HJ
    Studer, UE
    Thalmann, GN
    [J]. BJU INTERNATIONAL, 2002, 90 (06) : 579 - 585
  • [2] Bostwick DG, 1998, CANCER-AM CANCER SOC, V82, P2256, DOI 10.1002/(SICI)1097-0142(19980601)82:11<2256::AID-CNCR22>3.0.CO
  • [3] 2-S
  • [4] Expression analysis of δ-catenin and prostate-specific membrane antigen:: Their potential as diagnostic markers for prostate cancer
    Burger, MJ
    Tebay, MA
    Keith, PA
    Samaratunga, HM
    Clements, J
    Lavin, MF
    Gardiner, RA
    [J]. INTERNATIONAL JOURNAL OF CANCER, 2002, 100 (02) : 228 - 237
  • [5] MOLECULAR STAGING OF PROSTATE-CANCER .2. A COMPARISON OF THE APPLICATION OF AN ENHANCED REVERSE-TRANSCRIPTASE POLYMERASE CHAIN-REACTION ASSAY FOR PROSTATE-SPECIFIC ANTIGEN VERSUS PROSTATE-SPECIFIC MEMBRANE ANTIGEN
    CAMA, C
    OLSSON, CA
    RAFFO, AJ
    PERLMAN, H
    BUTTYAN, R
    OTOOLE, K
    MCMAHON, D
    BENSON, MC
    KATZ, AE
    [J]. JOURNAL OF UROLOGY, 1995, 153 (05) : 1373 - 1378
  • [6] Prostate-specific membrane antigen is a hydrolase with substrate and pharmacologic characteristics of a neuropeptidase
    Carter, RE
    Feldman, AR
    Coyle, JT
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1996, 93 (02) : 749 - 753
  • [7] Czerwinski M, 2002, METHOD ENZYMOL, V357, P170
  • [8] Gala JL, 1998, CLIN CHEM, V44, P472
  • [9] Grasso YZ, 1998, CANCER RES, V58, P1456
  • [10] Hara N, 2002, CLIN CANCER RES, V8, P1794